The T-box transcription factor brachyury behaves as a tumor suppressor in gliomas

The Journal of Pathology
Filipe PintoRui Manuel Reis

Abstract

The oncogene brachyury (TBXT) is a T-box transcription factor that is overexpressed in multiple solid tumors and is associated with tumor aggressiveness and poor patient prognosis. Gliomas comprise the most common and aggressive group of brain tumors, and at the present time the functional and clinical impact of brachyury expression has not been investigated previously in these neoplasms. Brachyury expression (mRNA and protein) was assessed in normal brain (n = 67), glioma tissues (n = 716) and cell lines (n = 42), and further in silico studies were undertaken using genomic databases totaling 3115 samples. Our glioma samples were analyzed for copy number (n = 372), promoter methylation status (n = 170), and mutation status (n = 1569 tissues and n = 52 cell lines) of the brachyury gene. The prognostic impact of brachyury expression was studied in 1524 glioma patient tumors. The functional impact of brachyury on glioma proliferation, viability, and cell death was evaluated both in vitro and in vivo. Brachyury was expressed in the normal brain, and significantly downregulated in glioma tissues. Loss of brachyury was associated with tumor aggressiveness and poor survival in glioma patients. Downregulation of brachyury was not assoc...Continue Reading

References

Aug 2, 2003·Oncogene·Ruty ShaiStanley F Nelson
Apr 8, 2004·Neoplasia : an International Journal for Oncology Research·Daniel R RhodesArul M Chinnaiyan
Sep 18, 2004·Cancer Research·William A FreijeStanley F Nelson
Feb 3, 2005·Acta Neuropathologica·Hiroko Ohgaki, Paul Kleihues
Nov 6, 2007·Biochemical and Biophysical Research Communications·Jong Chul ParkChulso Moon
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anastasia MuratMonika E Hegi
Aug 2, 2008·The New England Journal of Medicine·Patrick Y Wen, Santosh Kesari
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 3, 2008·Cancer Research·Mercedes RodriguezColin R Goding
Dec 16, 2010·BMC Genomics·Amandine EtcheverryJean Mosser
Jan 12, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nerbil KilicUdo Schumacher
May 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mario RoselliClaudia Palena
Dec 22, 2012·Neuro-oncology·Vera Miranda-GonçalvesFátima Baltazar
Mar 5, 2013·Annals of Surgical Oncology·Akira HaroYoshihiko Maehara
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
May 13, 2014·Journal of the National Cancer Institute·Claudia PalenaFiorella Guadagni
Jun 11, 2014·Nature Reviews. Neurology·Wolfgang WickGuido Reifenberger
Jul 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Filipe PintoRui M Reis
Sep 23, 2014·JAMA Neurology·Alissa A ThomasAntonio M Omuro
May 23, 2015·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Filipe PintoRui M Reis
Jul 16, 2015·Cancer Cell·Michael B FooteLuis A Diaz
Oct 12, 2017·Cell Reports·Sagar R ShahAlfredo Quiñones-Hinojosa

❮ Previous
Next ❯

Citations

Aug 14, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Filipe PintoRui Manuel Reis
Jul 18, 2021·Advances in Medical Sciences·Lucas Faria Abrahao-MachadoRui M Reis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms